The pharmacologic treatment of bipolar disorder

Journal of Clinical Psychiatry

Volumn 72, Issue 5, 2011, Pages 704-715

  Sachs, Gary S ^a,b   Dupuy, Jamie M ^a   Wittmann, Curtis W ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; BIFEPRUNOX; CARBAMAZEPINE; CHLORPROMAZINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LICARBAZEPINE; LITHIUM SALT; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PALIPERIDONE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTRALINE; TOPIRAMATE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ADJUVANT THERAPY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; HYPOMANIA; MAINTENANCE THERAPY; MIXED MANIA AND DEPRESSION; MONOTHERAPY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER; HUMANS; LITHIUM COMPOUNDS; RECURRENCE;

EID: 79959268613     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06523     Document Type: Review

References (153)

1. Angst J, Gamma A, Lewinsohn P. The evolving epidemiology of bipolar disorder. World Psychiatry. 2002;1(3):146-148. PubMed
2. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003;73(1-2):123-131. doi:10.1016/S0165-0327(02)032-4 PubMed (Pubitemid 36044640)
3. Kessler RC, Akiskal HS, Ames M, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of US workers. Am J Psychiatry. 2006;163(9):1561-1568. doi:10.176/api.ajp.163.9.1561 PubMed (Pubitemid 44465756)
4. Perlis RH, Miyahara S, Marangell LB, et al; STEP-BD Investigators. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry. 2004;55(9):875-881. doi:10.1016/j.biopsych. 204.01.02 PubMed
5. Leboyer M, Henry C, Paillere-Martinot ML, et al. Age at onset in bipolar affective disorders: a review. Bipolar Disord. 2005;7(2):111-118. doi:10.1/j.139-5618.205.0181.x PubMed
6. Simon GE. Social and economic burden of mood disorders. Biol Psychiatry. 2003;54(3):208-215. doi:10.1016/S06-323(03)0420-7 PubMed (Pubitemid 37267852)
7. Simon NM, Otto MW, Wisniewski SR, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2004;161(12):2222-2229. doi:10.176/api.ajp.161.12.2 PubMed (Pubitemid 39587287)
8. Summers M, Papadopoulou K, Bruno S, et al. Bipolar I and bipolar II disorder: cognition and emotion processing. Psychol Med. 2006;36(12):1799-1809. doi:10.1017/S032917060804 PubMed (Pubitemid 44824741)
9. Chengappa KN, Levine J, Gershon S, et al. Lifetime prevalence of substance or alcohol abuse and dependence among subjects with bipolar I and II disorders in a voluntary registry. Bipolar Disord. 2000;2(3, pt 1):191-195. doi:10.1034/j.139-5618.20.020306.x PubMed
10. Goldberg JF, Garno JL, Leon AC, et al. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry. 1999;60(11):733-740. doi:10.408/JCP.v60n103 PubMed
11. Brady KT, Lydiard RB. Bipolar affective disorder and substance abuse. J Clin Psychopharmacol. 1992;12(suppl):17S-22S. PubMed
12. Biederman J, Faraone SV, Wozniak J, et al. Parsing the association between bipolar, conduct, and substance use disorders: a familial risk analysis. Biol Psychiatry. 2000;48(11):1037-1044. doi:10.1016/S06-323(0)0906-9 PubMed
13. Winokur G, Turvey C, Akiskal H, et al. Alcoholism and drug abuse in three groups - bipolar I, unipolars and their acquaintances. J Affect Disord. 1998;50(2-3):81-89. doi:10.1016/S0165-0327(98)0108-6 PubMed
14. Venn HR, Gray JM, Montagne B, et al. Perception of facial expressions of emotion in bipolar disorder. Bipolar Disord. 2004;6(4):286-293. doi:10.1/j.139-5618.204.0121.x PubMed (Pubitemid 39077088)
15. Clark L, Kempton MJ, Scarnà A, et al. Sustained attention-deficit confirmed in euthymic bipolar disorder but not in first-degree relatives of bipolar patients or euthymic unipolar depression. Biol Psychiatry. 2005;57(2):183-187. doi:10.1016/j.biopsych.204.1.07 PubMed (Pubitemid 40094719)
16. Robinson LJ, Thompson JM, Gallagher P, et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord. 2006;93(1-3):105-115. doi:10.1016/j.jad.206.02.016 PubMed (Pubitemid 43816055)
17. Evans DL, Charney DS, Lewis L, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry. 2005;58(3):175-189. doi:10.1016/j.biopsych.205.05.01 PubMed (Pubitemid 41112265)
18. McIntyre RS, Konarski JZ, Soczynska JK, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv. 2006;57(8):1140-1144. doi:10.176/api.ps.57.8.140 PubMed (Pubitemid 44204907)
19. Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry. 2006;67(suppl 9):25-30, discussion 36-42. doi:10.408/JCP.106e16 PubMed
20. Wang PW, Sachs GS, Zarate CA, et al. Overweight and obesity in bipolar disorders. J Psychiatr Res. 2006;40(8):762-764. doi:10.1016/j.jpsychires.206.01. 07 PubMed (Pubitemid 44486246)
21. Arnold LM, Hudson JI, Keck PE, et al. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry. 2006;67(8):1219-1225. doi:10.408/JCP.v67n0807 PubMed (Pubitemid 44439693)
22. Hamelsky SW, Lipton RB. Psychiatric comorbidity of migraine. Headache. 2006;46(9):1327-1333. doi:10.1/j.1526-4610.206.0576.x PubMed (Pubitemid 44556425)
23. McKenna MT, Michaud CM, Murray CJ, et al. Assessing the burden of disease in the United States using disability-adjusted life years. Am J Prev Med. 2005;28(5):415-423. doi:10.1016/j.amepre.205.02.09 PubMed (Pubitemid 40719042)
24. Ustün TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004;184(5):386-392. doi:10.192/bjp.184.5.386 PubMed
25. Murray CJ, Lopez AD, Jamison DT. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bull World Health Organ. 1994;72(3):495-509. PubMed
26. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844-850. doi:10.101/archpsyc.58.9.84 PubMed (Pubitemid 32979302)
27. Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord. 2002;68(2-3):167-181. doi:10.1016/S0165-0327(01)037-9 PubMed (Pubitemid 34628324)
28. Sachs GS. Strategies for improving treatment of bipolar disorder: integration of measurement and management. Acta Psychiatr Scand Suppl. 2004;110(422):7-17. doi:10.1/j.160-047.204.0409.x PubMed
29. Dennehy EB, Bauer MS, Perlis RH, et al. Concordance with treatment guidelines for bipolar disorder: data from the Systematic Treatment Enhancement Program for Bipolar Disorder. Psychopharmacol Bull. 2007;40(3):72-84. PubMed
30. Sachs G. Managing Bipolar Affective Disorder. London, UK: Science Press Ltd; 2004.
31. Klerman GL. The psychiatric patient's right to effective treatment: implications of Osheroff v. Chestnut Lodge. Am J Psychiatry. 1990;147(4):409-418. PubMed
32. Altshuler LL, Post RM, Hellemann G, et al. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. J Clin Psychiatry. 2009;70(4):450-457. doi:10.408/JCP.08m04191 PubMed
33. Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry. 2010;167(7):792-800. doi:10.176/api.ajp.209.09020284 PubMed
34. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006;163(2):247-256. doi:10.176/api.ajp.163.2.247 PubMed (Pubitemid 44480844)
35. Kemp DE, Ganocy SJ, Brecher M, et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord. 2011;130(1-2):171-179. doi:10.1016/j.jad.2010.10.026 PubMed
36. Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2(10):349-352. PubMed
37. Bowden CL, Brugger AM, Swann AC, et al; The Depakote Mania Study Group. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA. 1994;271(12):918-924. doi:10.101/jama.271.12.918 PubMed
38. Prien RF, Caffey EM Jr, Klett CJ; Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Arch Gen Psychiatry. 1972;26(2):146-153. PubMed
39. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005;66(1):111-121. doi:10.408/JCP.v6n016 PubMed
40. Pope HG Jr, McElroy SL, Keck PE Jr, et al. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry. 1991;48(1):62-68. PubMed
41. Pande AC, Crockatt JG, Janney CA, et al; Gabapentin Bipolar Disorder Study Group. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Bipolar Disord. 2000;2(3, pt 2):249-255. doi:10.1034/j.139-5618.20.20305.x PubMed
42. Weisler RH, Kalali AH, Ketter TA; SPD417 Study Group. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry. 2004;65(4):478-484. doi:10.408/JCP. v65n0405 PubMed
43. Weisler RH, Hirschfeld R, Cutler AJ, et al; SPD417 Study Group. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs. 2006;20(3):219-231. doi:10.2165/023210-2062030-04 PubMed
44. Wagner KD, Kowatch RA, Emslie GJ, et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry. 2006;163(7):1179-1186. doi:10.176/api.ajp.163.7.179 PubMed (Pubitemid 44464445)
45. Kushner SF, Khan A, Lane R, et al. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord. 2006;8(1):15-27. doi:10.1/j.139-5618.206.0276.x PubMed (Pubitemid 43356017)
46. Tohen M, Sanger TM, McElroy SL, et al; Olanzapine HGEH Study Group. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry. 1999;156(5):702-709. PubMed
47. Tohen M, Jacobs TG, Grundy SL, et al; The Olanzapine HGGW Study Group. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2000;57(9):841-849. doi:10.101/archpsyc.57.9.841 PubMed
48. Study of licarbazepine in the treatment of manic episodes of bipolar disorder. ClinicalTrials.gov identifier: NCT00099229. http://clinicaltrials.gov/ ct2/show/NCT00099229?term=NCT00099229&rank=1. Updated December 12, 2007. Accessed March 31, 2011.
49. Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002;159(7):1146-1154. doi:10.176/api.ajp.159.7.146 PubMed (Pubitemid 34743254)
50. Yatham LN, Grossman F, Augustyns I, et al. Mood stabilisers plus risperidone or placebo in the treatment of acute mania: international, double-blind, randomised controlled trial. Br J Psychiatry. 2003;182(2):141-147. doi:10.192/bjp.182.2.141 PubMed (Pubitemid 36177237)
51. Hirschfeld RM, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161(6):1057-1065. doi:10.176/api.ajp.161.6.1057 PubMed (Pubitemid 38735992)
52. Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry. 2005;187(3):229-234. doi:10.192/bjp.187.3.29 PubMed (Pubitemid 41306103)
53. Keck PE Jr, Versiani M, Potkin S, et al; Ziprasidone in Mania Study Group. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160(4):741-748. doi:10.176/api.ajp.160.4.741 PubMed (Pubitemid 41079608)
54. Potkin SG, Keck PE Jr, Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol. 2005;25(4):301-310. doi:10.1097/01.jcp.0169068.3432.70 PubMed (Pubitemid 41065070)
55. Sachs G, Chengappa KN, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2004;6(3):213-223. (Pubitemid 38702297)
56. Yatham LN, Paulsson B, Mullen J, et al. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol. 2004;24(6):599-606. doi:10.1097/01.jcp.01487.6319.2f PubMed (Pubitemid 39518654)
57. Vieta E, Mullen J, Brecher M, et al. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin. 2005;21(6):923-934. doi:10.185/0307905X46340 PubMed (Pubitemid 40896240)
58. Ketter TA, Jones M, Paulsson B. Rates of remission/euthymia with quetiapine monotherapy compared with placebo in patients with acute mania. J Affect Disord. 2007;100(suppl 1):S45-S53. doi:10.1016/j.jad.207.02.06 PubMed (Pubitemid 46818456)
59. Yatham LN, Vieta E, Young AH, et al. A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. Int Clin Psychopharmacol. 2007;22(4):212-220. doi:10.1097/YIC.0b013e328080ca57 PubMed (Pubitemid 46801944)
60. Li H, Ma C, Wang G, et al. Response and remission rates in Chinese patients with bipolar mania treated for 4 weeks with either quetiapine or lithium: a randomized and double-blind study. Curr Med Res Opin. 2008;24(1):1-10. doi:10.185/0307908X25393 PubMed (Pubitemid 351160233)
61. Keck PE Jr, Marcus R, Tourkodimitris S, et al; Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160(9):1651-1658. doi:10.176/api.ajp.160.9.1651 PubMed (Pubitemid 41079552)
62. Sachs G, Sanchez R, Marcus R, et al; Aripiprazole Study Group. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006;20(4):536-546. doi:10.17/02698106059693 PubMed (Pubitemid 43875183)
63. Keck PE, Orsulak PJ, Cutler AJ, et al; CN138-135 Study Group. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord. 2009;112(1-3):36-49. doi:10.1016/j.jad.208.05.014 PubMed
64. McIntyre RS, Cohen M, Zhao J, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010;122(1-2):27-38. doi:10.1016/j.jad.209.12.028 PubMed
65. McIntyre RS, Cohen M, Zhao J, et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009;11(7):673-686. doi:10.1/j.139-5618.209.0748.x PubMed
66. Vieta E, Nuamah IF, Lim P, et al. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord. 2010;12(3):230-243. doi:10.1/j.139-5618.2010.0815.x PubMed
67. McIntyre RS, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol. 2005; 15(5):573-585. (Pubitemid 41219629)
68. Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2002;63(12):1148-1155. doi:10.408/JCP.v63n1210 PubMed (Pubitemid 36084060)
69. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003;60(12):1218-1226. doi:10.101/archpsyc.60.12. 1218 PubMed (Pubitemid 37494075)
70. Vieta E, Bourin M, Sanchez R, et al; Aripiprazole Study Group. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry. 2005;187(3):235-242. doi:10.192/bjp.187.3.235 PubMedoi:10.1016/j.euroneuro.205. 02.06 PubMed (Pubitemid 41306104)
71. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002;159(6):1011-1017. doi:10.176/api.ajp.159.6.101 PubMed (Pubitemid 34586948)
72. Ketter T, ed. Treatment of acute mania in bipolar disorder. Advances in Treatment of Bipolar Disorder. Washington, DC: American Psychiatric Publishing, Inc; 2005:11-24.
73. Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2006;67(4):509-516. doi:10.408/JCP.v67n0401 PubMed (Pubitemid 43764227)
74. Müller-Oerlinghausen B, Retzow A, Henn FA, et al; European Valproate Mania Study Group. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. J Clin Psychopharmacol. 2000;20(2):195-203. doi:10.1097/04714-2040-012 PubMed (Pubitemid 30202362)
75. Post RM, Ketter TA, Pazzaglia PJ, et al. Rational polypharmacy in the bipolar affective disorders. Epilepsy Res Suppl. 1996;11:153-180. PubMed
76. Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry. 1998;155(1):12-21. PubMed
77. Rosa AR, Fountoulakis K, Siamouli M, et al. Is anticonvulsant treatment of mania a class effect? data from randomized clinical trials [published online ahead of print December 15, 2009]. CNS Neurosci Ther. 2009. doi:10.1/j.175-5949. 209.089.x PubMed
78. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158(6):906-912. doi:10.176/api.ajp.158.6.906 PubMed (Pubitemid 32547620)
79. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry. 1994;55(9):391-393. PubMed
80. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079-1088. doi:10.101/archpsyc.60.1.1079 PubMed (Pubitemid 37429647)
81. Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry. 1991;148(7):910-916. PubMed
82. Thase ME, Mallinger AG, McKnight D, et al. Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry. 1992;149(2):195-198. PubMed
83. van der Loos ML, Mulder PG, Hartong EG, et al; LamLit Study Group. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(2):223-231. doi:10.408/JCP.08m04152 PubMed
84. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry. 1984;41(11):1096-1104. PubMed
85. McElroy SL, Weisler RH, Chang W, et al; EMBOLDEN II (Trial D1447C00134) Investigators. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71(2):163-174. doi:10.408/JCP.08m04942gre PubMed
86. Young AH, McElroy SL, Bauer M, et al; EMBOLDEN I (Trial 001) Investigators. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010;71(2):150-162. doi:10.408/JCP.08m0495gre PubMed
87. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351-1360. doi:10.176/api.ajp.162.7. 1351 PubMed (Pubitemid 40905587)
88. Suppes T, Datto C, Minkwitz M, et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010;121(1-2):106-115. doi:10.1016/j.jad. 209.10.07 PubMed
89. Thase ME, Macfadden W, Weisler RH, et al; BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600-609. doi:10.1097/01.jcp.0248603.76231.b7 PubMed (Pubitemid 44772737)
90. Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008;28(1):13-20. doi:10.1097/jcp. 0b013e3181618eb4 PubMed
91. Sachs GS, Ice K, Chappell P, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder. J Clin Psychiatry. In press.
92. Multicenter, randomized, double-blind, placebo-controlled, parallel-group study of bifeprunox in the treatment of depression in outpatients with bipolar disorder. ClinicalTrials.gov identifier: NCT00134459. http://clinicaltrials.gov/ ct2/results?term=NCT00134459. Updated July 6, 2009. Accessed March 31, 2011.
93. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711-1722. doi:10.1056/NEJMoa064135 PubMed (Pubitemid 46658703)
94. Calabrese JR, Bowden CL, Sachs G, et al; Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64(9):1013-1024. doi:10.408/JCP.v64n0906 PubMed (Pubitemid 37158246)
95. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009;194(1):4-9. doi:10.192/bjp.bp.107.048504 PubMed
96. Perlis RH, Adams DH, Fijal B, et al. Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. J Clin Psychiatry. 2010;71(5):599-605. doi:10.408/JCP.08m04632gre PubMed
97. Sachs GS. Understanding why studies fail: what can you see through a third blind eye? Presented at the 15th Biennial Winter Workshop in Psychoses; November 15-18, 2009; Barcelona, Spain.
98. Sachs GS. Found in translation: concordance across global clinical trials. Presented at the 49th Annual NCDEU Meeting; June 29-July 2, 2009; Hollywood, Florida.
99. Baldessarini R, Henk H, Sklar A, et al. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv. 2008;59(10):1175-1183.
100. Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161(9):1537-1547. doi:10.176/api.ajp.161.9.1537 PubMed (Pubitemid 39201448)
101. Sachs GS. STEP-BD Update: what have we learned. Presented at the 5th International Conference on Bipolar Disorder; June 12-14, 2003; Pittsburgh, Pennsylvania.
102. Goldberg JF, Brooks JO 3rd, Kurita K, et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry. 2009;70(2):155-162. doi:10.408/JCP. 08m04301 PubMed
103. Altshuler L, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry. 2003;160(7):1252-1262. doi:10.176/api.ajp.160.7.1252 PubMed (Pubitemid 41070941)
104. Suppes T, Hirschfeld RM, Vieta E, et al. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry. 2008;9(3):198-211. doi:10.1080/1562970701317265 PubMed
105. Amsterdam JD, Shults J. Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. Int Clin Psychopharmacol. 2005;20(5):257-264. doi:10.1097/01.yic. 0171519.64080.c9 PubMed (Pubitemid 41192146)
106. Amsterdam JD, Shults J, Brunswick DJ, et al. Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression - low manic switch rate. Bipolar Disord. 2004;6(1):75-81. doi:10.1046/j.139-5618.203.083.x PubMed (Pubitemid 38256507)
107. Amsterdam JD, Wang CH, Shwarz M, et al. Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial. J Affect Disord. 2009;112(1-3):219-230. doi:10.1016/j.jad.208.03.029 PubMed
108. Amsterdam JD, Wang G, Shults J. Venlafaxine monotherapy in bipolar type II depressed patients unresponsive to prior lithium monotherapy. Acta Psychiatr Scand. 2010;121(3):201-208. doi:10.1/j.160-047.209.01462.x PubMed
109. Kraepelin E. Manic-Depressive Insanity and Paranoia. Edinburgh, UK: E & S Livingstone; 1921.
110. Angst J. Switch from depression to mania - a record study over decades between 1920 and 1982. Psychopathology. 1985;18(2-3):140-154. doi:10.159/028427 PubMed
111. Ghaemi SN. Treatment of rapid-cycling bipolar disorder: are antidepressants mood destabilizers? Am J Psychiatry. 2008;165(3):300-302. doi:10.176/api.ajp.207.07121931 PubMed
112. Goodwin FK. The biology of recurrence: new directions for the pharmacologic bridge. J Clin Psychiatry. 1989;50(suppl):40-44, discussion 45-47. PubMed
113. Wehr T, Goodwin FK. Tricyclics modulate frequency of mood cycles. Chronobiologia. 1979;6(4):377-385. PubMed
114. Wehr TA, Goodwin FK. Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry. 1979;36(5):555-559. PubMed
115. Ahlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manic-depressive illness: a comparison with lithium. Acta Psychiatr Scand. 1981;64(3):226-237. doi:10.1/j.160-047.1981.tb078.x PubMed (Pubitemid 11026617)
116. Zarate CA Jr, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry. 2004;161(1):169-171. doi:10.176/api.ajp.161.1.169 PubMed (Pubitemid 38419326)
117. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry. 2006;189(2):124-131. doi:10.192/bjp.bp.105.013045 PubMed (Pubitemid 44231270)
118. Altshuler LL, Suppes T, Black DO, et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry. 2006;163(2):313-315. doi:10.176/api.ajp.163.2.313 PubMed (Pubitemid 44480853)
119. Frye MA, Helleman G, McElroy SL, et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry. 2009;166(2):164-172. doi:10.176/api.ajp.208.0803032 PubMed
120. Bowden CL, Calabrese JR, McElroy SL, et al; Divalproex Maintenance Study Group. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry. 2000;57(5):481-489. doi:10.101/archpsyc.57.5.481 PubMed
121. Baldessarini RJ, Tondo L. Recurrence risk in bipolar manic-depressive disorders after discontinuing lithium maintenance treatment: an overview. Clin Drug Investig. 1998;15(4):337-351. doi:10.2165/0401-19815040-010 PubMed (Pubitemid 28204008)
122. Baldessarini RJ, Tondo L, Floris G, et al. Reduced morbidity after gradual discontinuation of lithium treatment for bipolar I and II disorders: a replication study. Am J Psychiatry. 1997;154(4):551-553. PubMed
123. Baldessarini RJ, Tondo L, Ghiani C, et al. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry. 2010;167(8):934-941. doi:10.176/api.ajp.2010.0906080 PubMed
124. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry. 1999;60(suppl 2):77-84, discussion 111-116. PubMed
125. Baldessarini RJ, Tondo L, Viguera AC. Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications. Bipolar Disord. 1999;1(1):17-24. doi:10.1034/j.139-5618.19.10106.x PubMed
126. Faedda GL, Tondo L, Baldessarini RJ. Lithium discontinuation: uncovering latent bipolar disorder? Am J Psychiatry. 2001;158(8):1337-1339. doi:10.176/api.ajp.158.8.137-a PubMed
127. Faedda GL, Tondo L, Baldessarini RJ, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry. 1993;50(6):448-455. PubMed
128. Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry. 1991;48(12):1082-1088. PubMed
129. Tondo L, Baldessarini RJ, Floris G, et al. Effectiveness of restarting lithium treatment after its discontinuation in bipolar I and bipolar II disorders. Am J Psychiatry. 1997;154(4):548-550. PubMed
130. Viguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164(12):1817-1824, quiz 1923. doi:10.176/api.ajp.207.06101639 PubMed
131. Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med. 1989;321(22):1489-1493. doi:10.1056/NEJM1989130321201 PubMed (Pubitemid 20015538)
132. Ghaemi SN, Ostacher MM, El-Mallakh RS, et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry. 2010;71(4):372-380. doi:10.408/JCP.08m04909gre PubMed
133. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry. 2004;65(3):432-441. doi:10.408/JCP. v65n0321 PubMed
134. Bowden CL, Calabrese JR, Sachs G, et al; Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60(4):392-400. doi:10.101/archpsyc.60.4.392 PubMed
135. Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005;162(7):1281-1290. doi:10.176/api.ajp.162.7.1281 PubMed (Pubitemid 40905578)
136. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003;160(7):1263-1271. doi:10.176/api.ajp.160.7.1263 PubMed (Pubitemid 41070942)
137. Keck PE Jr, Calabrese JR, McQuade RD, et al; Aripiprazole Study Group. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006;67(4):626-637. doi:10.408/JCP.v67n0414 PubMed (Pubitemid 43764240)
138. Vieta E, Suppes T, Eggens I, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 2008;109(3):251-263. doi:10.1016/j.jad.208.06.01 PubMed
139. Bowden CL, Vieta E, Ice KS, et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry. 2010;71(2):130-137. doi:10.408/JCP. 09m05482yel PubMed
140. Macfadden W, Alphs L, Haskins JT, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord. 2009;11(8):827-839. doi:10.1/j.139-5618.209.0761.x PubMed
141. Geddes JR, Goodwin GM, Rendell J, et al; BALANCE investigators and collaborators. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375(9712):385-395. doi:10.1016/S0140-6736(09)61828-6 PubMed
142. Goodwin FK, Jamison KR, Ghaemi SN, eds. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. 2nd ed. New York, NY: Oxford University Press; 2007.
143. Otto MW, Simon NM, Wisniewski SR, et al; STEP-BD Investigators. Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry. 2006;189(1):20-25. doi:10.192/bjp.bp.104.073 PubMed (Pubitemid 44023325)
144. Baldassano CF. Illness course, comorbidity, gender, and suicidality in patients with bipolar disorder. J Clin Psychiatry. 2006;67(suppl 11):8-11. PubMed
145. Judd LL, Schettler PJ, Akiskal HS, et al. Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Arch Gen Psychiatry. 2008;65(4):386-394. doi:10.101/archpsyc.65.4.386 PubMed (Pubitemid 351519888)
146. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2006;163(2):217-224. (Pubitemid 44480840)
147. Marangell LB, Dennehy EB, Miyahara S, et al. The functional impact of subsyndromal depressive symptoms in bipolar disorder: data from STEP-BD. J Affect Disord. 2009;114(1-3):58-67. doi:10.1016/j.jad.208.07.06 PubMed
148. Levin FR, Hennessy G. Bipolar disorder and substance abuse. Biol Psychiatry. 2004;56(10):738-748. PubMed
149. Nierenberg AA, Miyahara S, Spencer T, et al; STEP-BD Investigators. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psychiatry. 2005;57(11):1467-1473. doi:10.1016/j.biopsych.205.01.036 PubMed
150. Freeman MP, Smith KW, Freeman SA, et al. The impact of reproductive events on the course of bipolar disorder in women. J Clin Psychiatry. 2002;63(4):284-287. doi:10.408/JCP.v63n0403 PubMed
151. Robertson Blackmore E, Craddock N, Walters J, et al. Is the perimenopause a time of increased risk of recurrence in women with a history of bipolar affective postpartum psychosis? a case series. Arch Women Ment Health. 2008;11(1):75-78. doi:10.107/s0737-08-0215-2 PubMed
152. Grof P, Duffy A, Cavazzoni P, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 2002;63(10):942-947. doi:10.408/JCP. v63n1013 PubMed
153. Perlis RH, Smoller JW, Ferreira MA, et al. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry. 2009;166(6):718-725.